Dalbavancin (Dalvance) didn't deliver better overall outcomes compared with standard treatment in adults with complicated ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Astellas Pharma Inc. ADR company and executive profile by Barron's. View the latest ALPMY company infomation and executive bios.

About Astellas Pharma Inc. ADR Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

The team, led by Dr Phillip Jenkins, a postdoctoral fellow in clinical informatics at Oregon Health & Science University, ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Part of Foundry’s global CIO awards program, the awards recognise IT teams that exemplify excellence in specific areas.

DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report ...

The ADC market is rapidly advancing due to next-gen oncology therapeutics and increased R&D, offering significant opportunities for addressing treatment-resistant cancersDublin, Aug. 13, 2025 (GLOBE ...